Spherix Media
Across the pharma lifecycle, an accurate and complete market view is essential to stay ahead of the curve and uncover emerging healthcare trends.
Following a period of stability in the US biologic asthma market, new data reveals hidden opportunities for differentiation and growing prescriber interest in emerging pipeline therapies Exton, PA, May 13, 2025 – Although no new biologics for asthma have been approved since the 2021 launch of Tezspire (Amgen/AstraZeneca), recent insights
Products such as Tarpeyo (Calliditas), Filspari (Travere) and now Novartis’ Fabhalta and Venrafia provide physicians more options than ever before. Exton, PA, May 8, 2025 – With multiple targeted therapies now available and SGLT2 inhibitors broadly embraced, nephrologists across the globe are redefining how they manage IgA Nephropathy (IgAN) patients.
US hematologists express growing confidence in curative gene therapies such as Casgevy and Lyfgenia, while also showing heightened enthusiasm for next-generation disease-modifying agents. Exton, PA, May 01, 2025 – Patients with sickle cell disease (SCD) continue to face severe complications, despite advances in treatment that have helped mitigate some risks.
The ACR’s updated lupus nephritis treatment guidelines emphasize triple therapy regimens anchored by Benlysta or a calcineurin inhibitor, while Gazyva’s potential role in the evolving landscape remains to be established as the field continues to advance. Exton, PA., April 30, 2025 – The American College of Rheumatology’s (ACR) newly updated
Perceived first-line utility, patient pool expansion, and paradigm-shifting potential distinguish Icotrokinra in the eyes of US dermatologists EXTON, PA, April 14, 2025 – Johnson & Johnson’s recent announcement of positive Phase 3 data for its oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), has sparked notable enthusiasm across the dermatology community. According
Dermatologists rely heavily on topical therapies for cutaneous lupus erythematosus (CLE), but are increasingly interested in systemic agents with user-friendly formulations and dermatology-relevant experience such as deucravacitinib (Sotyktu BMS), an oral TYK2 inhibitor currently approved for psoriasis. Familiarity with its mechanism and a favorable safety profile have positioned deucravacitinib as
Rheumatologists and dermatologists highlight Saphnelo, Sotyktu, and litifilimab as leading candidates to address unmet needs in CLE patients, particularly those with systemic involvement Exton, PA., April 10, 2025 – As treatment approaches for cutaneous lupus erythematosus (CLE) continue to evolve, new data from Spherix Global Insights shed light on how
Recently released research reveals key insights into physician perspectives, practice management changes, and expected prescribing changes resulting from recent IRA-driven Medicare changes. EXTON, PA., April 10, 2025 — In 2025, the Inflation Reduction Act (IRA) introduced significant Medicare reforms designed to reduce financial burdens for patients, including a new cap
Spherix’s inaugural Patient Dynamix™: IgAN research, focusing on real-world patient experiences, reveals unmet needs in disease education, affordability, and care navigation EXTON, PA – April 8, 2025 – Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at
Gastroenterologists are enthusiastic about Tremfya’s subcutaneous induction option in Crohn’s disease, a key potential brand differentiator, according to Spherix Global Insights. EXTON, PA., March 28, 2025 – The treatment landscape for Crohn’s disease continues to evolve with the recent FDA approval of Johnson and Johnson Innovative Medicine’s Tremfya (guselkumab). This
While interest in BMS’s pipeline asset is strong, some prescribers are underwhelmed by ACR20 endpoint. EXTON, PA, March 27, 2025 – In late 2024, Bristol Myers Squibb announced positive topline results from its pivotal Phase 3 trials, POETYK PsA-1 and PsA-2, evaluating Sotyktu (deucravacitinib) in adults with active psoriatic arthritis
Exton, PA, March 27, 2025 – Tucker Hurtado, Vice President of Product Planning at Spherix Global Insights, has been named a 2025 Luminary by the Healthcare Businesswomen’s Association (HBA). She will be recognized at the organization’s annual Woman of the Year celebration, taking place in Chicago on May 9, 2025.
As the IgAN market expands with the introduction of branded therapies, nephrologists express growing interest in the early-line potential of dual APRIL/BAFF inhibitors and atrasentan. [Exton, PA, March 26, 2025] – Nearly all nephrologists agree that early and aggressive intervention is essential for improving outcomes in IgA nephropathy (IgAN). However,
Hematologists remain undecided on the long-term role of newly launched hemophilia therapies, particularly as the industry awaits word on Sanofi’s fitusiran by the end of March. Exton, PA, March 26, 2025 – The hemophilia treatment landscape is rapidly evolving, with newly launched therapies and gene therapies joining factor replacement therapies,
AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to biosimilars and new options enter the market. Immunology physicians are starting to adjust to the new treatment paradigm brought on by the entry of Humira biosimilars, sending sales of AbbVie’s
Latest independent research from Spherix Global Insights highlights growing urgency to treat PNH with complement or factor inhibitors, shifting physician preferences, and the impact of biosimilar eculizumab entering the market. [Exton, PA, March 18, 2025] – Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and debilitating blood disorder that affects approximately
Media
04.08.2024
Pfizer’s Velsipity poised to outpace BMS’ Zeposia in ulcerative colitis market, but must head off further competition: analysts
04.08.2024
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
04.05.2024
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of…
03.22.2024
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for…
